ValiMed(TM) Medication Signature Library Continues to Grow; CDEX Adds 14 New Medication Signatures
ROCKVILLE, Md., Jun 27, 2006 (BUSINESS WIRE) -- CDEX, Inc. (OTCBB: CEXI)
announced today that it has added fourteen medications to the signature library
of the ValiMed Medication Validation System. This brings the total formulary of
medication and drug signatures in the library to 47 signatures.
These new signatures include narcotics and antibiotics and expand the system's
ability to validate additional high risk medications and therefore increase the
value of the ValiMed (TM) Patient Safety Solution. The new antibiotics that have
been added to the signature library have been documented in the literature as
being involved in medication errors. The additional narcotics that have been
added will broaden the scope of the ValiMed (TM) Impaired Clinician Solution and
the list includes the first liquid oral medication.
"The addition of these new signatures demonstrates the company's commitment to
value enhancement through additional research and development, and is yet
another example of the implementation of the company's growth strategy. CDEX
will continue to expand the formulary of its signature library by adding new
medications that will add value by allowing our clients to validate an ever
increasing number of medications and drugs. The continuing expansion of new
medication signatures not only adds value to our clients' medication validation
efforts, but also provides CDEX with additional revenue potential," stated Jim
Griffin, President and CEO of CDEX, Inc.
The ValiMed medication library currently consists of 47 narcotics and patient
care medications, and is scheduled to be expanded to more than 140 medications,
doses and diluents, by the end of the year. The improved capabilities and
expansion of the medication signature library will enable the ValiMed(TM)
Medication Validation System to become an essential tool for improving patient
safety.
About CDEX Inc.
CDEX Inc. is a technology development company with a current focus on developing
and marketing products using chemical detection and validation technologies. At
present, CDEX is devoting its resources to two distinct areas: (i) and quality
assurance (e.g., validation of prescription medication and detection of
counterfeit or sub-par products for brand protection). ValiMed is one line of
CDEX products for the healthcare market; and (ii) identification of substances
of concern (e.g., illegal drugs for law enforcement in the homeland security
market). CDEX is headquartered in Rockville, Maryland with its research and
development laboratory in Tucson, Arizona. For more information, visit
www.cdex-inc.com.
Any statements made in this press release which contain information that is not
historical are essentially forward-looking. Many forward-looking statements can
be identified by the use of words such as "expects," "plans," "may,"
"anticipates," "believes," "should," "intends," "estimates," and other words of
similar meaning. These statements are subject to risks and uncertainties that
cannot be predicted or quantified and, consequently, actual results may differ
materially from those expressed or implied by such forward-looking statements.
Such risks are detailed from time-to-time in filings with the Securities and
Exchange Commission. There is no obligation to publicly update any
forward-looking statements.
SOURCE: CDEX, Inc.
|
